Prevnar 20 is named as an intervention in 19 current clinical trials in our USA, Japan, Canada, Poland, China, UK, Spain, Netherlands, Brazil, Mexico, South Korea, Taiwan, Germany and Australia registers. 11 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Pfizer (9). The most-studied condition is Pneumococcal Disease.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Pfizer | 9 |
| Merck Sharp & Dohme LLC | 3 |
| Vaxcyte, Inc | 3 |
| Sanofi | 2 |
| Chengdu New Radiomedicine Technology Co. LTD | 1 |
| Sanofi Pasteur, a Sanofi Company | 1 |
A trial with sites in more than one country appears in each of those registers.
19 current trials in our USA, Japan, Canada, Poland, China, UK, Spain, Netherlands, Brazil, Mexico, South Korea, Taiwan, Germany and Australia registers name Prevnar 20 (also registered as 20-valent pneumococcal conjugate vaccine) as a drug or biological intervention, as of the registry sync on 1 October 2026. Completed and withdrawn studies are not counted.
Yes. 11 of the 19 trials are recruiting: 10 with sites in USA, 2 with sites in Japan, 2 with sites in Canada, 1 with sites in Poland, 1 with sites in China, 1 with sites in UK, 1 with sites in Spain, 1 with sites in Netherlands, 1 with sites in Brazil, 1 with sites in Mexico, 1 with sites in South Korea, 1 with sites in Taiwan, 1 with sites in Germany and 1 with sites in Australia. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Pfizer (9), Merck Sharp & Dohme LLC (3), Vaxcyte, Inc (3) and Sanofi (2), among 6 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Prevnar 20 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Prevnar 20 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Prevnar 20 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 1 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.